These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18172938)

  • 1. HIV diagnosis at CD4 count above 500 cells/mm3 and progression to below 350 cells/mm3 without antiretroviral therapy.
    UK Collaborative HIV Cohort (CHIC) Study Steering Committee
    J Acquir Immune Defic Syndr; 2007 Nov; 46(3):275-8. PubMed ID: 18172938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
    García F; de Lazzari E; Plana M; Castro P; Mestre G; Nomdedeu M; Fumero E; Martínez E; Mallolas J; Blanco JL; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):702-13. PubMed ID: 15167289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.
    Ekouévi DK; Avettand-Fènoël V; Tchounga BK; Coffie PA; Sawadogo A; Minta D; Minga A; Eholie SP; Plantier JC; Damond F; Dabis F; Rouzioux C;
    PLoS One; 2015; 10(6):e0129886. PubMed ID: 26111242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
    Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
    JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ cell count recovery after initiation of antiretroviral therapy in HIV-infected Ethiopian adults.
    Fiseha T; Ebrahim H; Ebrahim E; Gebreweld A
    PLoS One; 2022; 17(3):e0265740. PubMed ID: 35324948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.
    Miller V; Mocroft A; Reiss P; Katlama C; Papadopoulos AI; Katzenstein T; van Lunzen J; Antunes F; Phillips AN; Lundgren JD
    Ann Intern Med; 1999 Apr; 130(7):570-7. PubMed ID: 10189326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunistic infection at the start of antiretroviral therapy and baseline CD4+ count less than 50 cells/mm3 are associated with poor immunological recovery.
    Tilak A; Shenoy S; Varma M; Kamath A; Tripathy A; Sori R; Saravu K
    J Basic Clin Physiol Pharmacol; 2019 Mar; 30(2):163-171. PubMed ID: 30901314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
    Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
    Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003.
    Stöhr W; Dunn D; Porter K; Hill T; Gazzard B; Walsh J; Gilson R; Easterbrook P; Fisher M; Johnson M; Delpech V; Phillips A; Sabin C;
    HIV Med; 2007 Apr; 8(3):135-41. PubMed ID: 17461856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
    Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
    J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.
    Porter K; Walker S; Hill T; Anderson J; Leen C; Johnson M; Gazzard B; Walsh J; Fisher M; Orkin C; Schwenk A; Gilson R; Easterbrook P; Delpech V; Sabin CA;
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):202-5. PubMed ID: 17971709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.
    Baker JV; Neuhaus J; Duprez D; Kuller LH; Tracy R; Belloso WH; De Wit S; Drummond F; Lane HC; Ledergerber B; Lundgren J; Nixon DE; Paton NI; Neaton JD;
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):36-43. PubMed ID: 20930640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.
    Tan DHS; Raboud JM; Szadkowski L; Grinsztejn B; Madruga JV; Figueroa MI; Cahn P; Barton SE; Clarke A; Fox J; Zubyk W; Walmsley SL;
    J Antimicrob Chemother; 2019 Feb; 74(2):480-488. PubMed ID: 30376108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
    Bwire R; Nagelkerke NJ; Borgdorff MW
    Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.
    Piroth L; Fournel I; Mahy S; Yazdanpanah Y; Rey D; Rabaud C; Faller JP; Hoen B; Fardeheb M; Quantin C; Chavanet P; Binquet C;
    Epidemiol Infect; 2011 Dec; 139(12):1835-44. PubMed ID: 21232172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ART initiation in an outpatient treatment center in Dakar, Senegal: A retrospective cohort analysis (1998-2015).
    Ngom NF; Faye MA; Ndiaye K; Thiam A; Ndour CT; Etard JF; Sow PS; Seydi M; Delaporte E; Cournil A
    PLoS One; 2018; 13(9):e0202984. PubMed ID: 30231075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.
    O'Connor JL; Smith CJ; Lampe FC; Hill T; Gompels M; Hay P; Chadwick D; Fisher M; Ainsworth J; Gilson R; Mackie N; Anderson J; Orkin C; Nelson M; Kegg S; Leen C; Palfreeman A; Post F; Johnson M; Sabin CA; Phillips AN;
    AIDS; 2014 Mar; 28(6):919-24. PubMed ID: 24335482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.